Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- University of Alabama at Birmingham
- Registration Number
- NCT04149275
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT04145115
- Locations
- 🇺🇸
Cancer Hematology Centers - Flint, Flint, Michigan, United States
🇺🇸Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC
- Conditions
- Interventions
- First Posted Date
- 2019-10-28
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 24
- Registration Number
- NCT04141644
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Kidney Cancer Research Bureau
- Target Recruit Count
- 8
- Registration Number
- NCT04134182
- Locations
- 🇷🇺
Russian Scientific Center of Roentgenoradiology, Moscow, Russian Federation
🇷🇺N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation
Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 44
- Registration Number
- NCT04133948
- Locations
- 🇳🇱
Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-10-11
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Johannes Laengle, MD, PhD
- Target Recruit Count
- 80
- Registration Number
- NCT04124601
- Locations
- 🇦🇹
State Hospital Wiener Neustadt, Wiener Neustadt, Lower Austria, Austria
🇦🇹Hospital North - Clinic Floridsdorf, Vienna, Austria
🇦🇹Medical University of Vienna, Vienna, Austria
Ipilimumab + Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Kristen Ganjoo
- Target Recruit Count
- 30
- Registration Number
- NCT04118166
- Locations
- 🇺🇸
Stanford Medical Center, Stanford, California, United States
Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-10-07
- Last Posted Date
- 2024-03-01
- Target Recruit Count
- 30
- Registration Number
- NCT04117087
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Microbiome Immunotherapy Toxicity and Response Evaluation
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- CCTU- Cancer Theme
- Target Recruit Count
- 1800
- Registration Number
- NCT04107168
- Locations
- 🇬🇧
University Hospitals Dorest NHS Foundation Trust, Bournemouth, United Kingdom
🇬🇧Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom
🇬🇧Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2019-09-17
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 14
- Registration Number
- NCT04091750
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Medstar Franklin Square Medical Center, Harry and Jeanette Weinberg Cancer Institute, Baltimore, Maryland, United States
🇺🇸Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.